• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Ambrx

edit

Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.

Recent Milestones

edit

• 
  Ambrx received $10M in Series D funding. (4/1/09)
  Posted 4/13/09 at 1:07pm via onbiovc.com
• 
  Ambrx added Cris Calsada as Vice President of Finance.
  Posted 11/12/12 at 5:29am
• 
  Ambrx added Ho Sung Cho, Ph.D. as Chief Technology Officer.
  Posted 11/12/12 at 5:29am
• 
  Ambrx added Simon Allen as Chief Business Officer.
  Posted 11/12/12 at 5:29am
• 
  Ambrx added Lawson Macartney as CEO.
  Posted 1/7/13 at 8:50pm

Videos

Screenshots

edit

Sources

1. Ambrx, Inc.: Series D $10M (onbiovc.com) [edit]